The Intriguing Potential of Available, Low Cost Drug for Alcoholism as Antiviral Against COVID-19

In what could be considered  a striking discovery researchers form Harvard Medical School and Boston Children’s Hospital found that people taking the alcoholism drug disulfiram were 34% less likely to succumb to a SARS-CoV-2 infection, the virus behind COVID-19. Noteworthy none of the participants taking disulfiram died from COVID-19, as compared to 3% of the observational study population not prescribed to the drug used to combat alcoholism.  Could this medicine used to treat alcoholism in the United States for decades be used as a way to lower risk against COVID-19 infection and death? One randomized controlled study sponsored by University of California, San Francisco is ongoing while another one will commence.

In an observational study the research team led by corresponding author Chris Sander, PhD evaluated data from over 944,000 U.S. vets who had at a minimum one COVID-19 test between February 2020 and February 2021. A total of 2,200 of the study subjects were prescribed the alcoholism medication.  The results of the study were recently published in PLOS One and supported the initiation of a small Phase 2 clinical trial of disulfiram in patients with moderate CO...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee